Department of Obstetrics, Gynaecology and Reproduction Instituto Universitario Dexeus
Barcelona, 08028, Spain
NCT Number: NCT03395665
The development and improvement in Preimplantation genetic diagnosis/screening (PGS) in association with the efficacy and security of vitrification and trophectoderm biopsy, more efficient stimulation schemes and laboratory improvements in culture and embryo selection have contributed to high success of the assisted reproductive technologies(ART). Transferring an euploid embryo avoids one of the main reasons of miscarriage and implantation failure ( Rubio et al, 22016) and overcomes one of the most important confounding factors. Usually, the transfer of euploid embryos is performed under standard hormone replacement therapy (HRT) and are referred to as FET-PGS cycles( Frozen embryo transfer). The study of FET-PGS cycles with the transfer of a single euploid blastocyst is the best model for evaluation of the impact of the endometrial preparation . Among factors influencing FET outcomes, patient's age, endometrial preparation, endometrium thickness, endometrial pattern, number and quality of embryos transferred , difficulty at ET, recently P4 have received more attention .
The importance of Progesterone (P4) in embryo implantation has been widely studied. P4 plays an important role in endometrial gland formation, embryonic implantation and pregnancy maintenance, both in natural and artificial cycles.
Looking for future studies?
Notify Me18 year–43 year
Female
Observational
Barcelona, 08028, Spain
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Estradiol level measured at previous day of embryo transfer procedure
Progesterone level measured at previous day of embryo transfer procedure
Endometrial thickness measured at previous day of embryo transfer procedure
Time frame: Ten months after transfer procedure
Time frame: Any pregnancy loss before week 20
Miscarriage was defined as a loss following a positive pregnancy test and/or detectable Gestational sac
Time frame: 6 weeks after transfer procedure
Fundacion Dexeus
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05290051
Abortion, Spontaneous, Congenital Abnormalities
Paris, France
View Trial DetailsNCT01363596
Abortion, Spontaneous, Female Urogenital Diseases and Pregnancy Complications
Baton Rouge, Louisiana, United States
View Trial DetailsNCT03218878
Abortion, Spontaneous, Female Urogenital Diseases and Pregnancy Complications
Basking Ridge, New Jersey, United States
View Trial DetailsNCT00994812
Abortion, Spontaneous, Adnexal Diseases
Helsinki, Finland
View Trial Details